Page header

Recommendation of the President – Ladinorm (ramipril + bisoprolol fumarate)

On 23 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 56/2026 on the inclusion of the medicinal product Ladinorm (ramipril + bisoprolol fumarate) in the reimbursement program for all registered indications as of the date of this decision

Publication in Public Information Bulletin (BIP) >>